Safety of Targeted Perioperative Mupirocin Treatment for Preventing Infections After Cardiac Surgery

Annals of Thoracic Surgery

Volumn 81, Issue 6, 2006, Pages 2183-2188

  Shrestha, Nabin K ^a   Banbury, Michael K ^a   Weber, Monica ^a   Cwynar, Roberta E ^a   Lober, Cheryl ^a   Procop, Gary W ^a   Karafa, Matthew T ^a   Gordon, Steven M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PSEUDOMONIC ACID;

ADULT; ARTICLE; BACTERIAL INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG SAFETY; FEMALE; HEART SURGERY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; PERIOPERATIVE PERIOD; POLYMERASE CHAIN REACTION; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; SURGICAL INFECTION;

AGED; ANTIBIOTIC PROPHYLAXIS; BACTEREMIA; CARDIAC SURGICAL PROCEDURES; CARRIER STATE; COHORT STUDIES; COMORBIDITY; DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUPIROCIN; NASAL CAVITY; OHIO; PATIENT SELECTION; POLYMERASE CHAIN REACTION; PREANESTHETIC MEDICATION; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; SURGICAL WOUND INFECTION; UNNECESSARY PROCEDURES;

EID: 33646824130     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.athoracsur.2006.01.009     Document Type: Article

References (21)

1. National Nosocomial Infections Surveillance (NNIS) Report. Data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) system. Am J Infect Control 24 (1996) 380-388
2. von Eiff C., Becker K., Machka K., Stammer H., and Peters G. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study group. N Engl J Med 344 (2001) 11-16
3. Wenzel R.P., and Perl T.M. The significance of nasal carriage of Staphylococcus aureus and the incidence of postoperative wound infection. J Hosp Infect 31 (1995) 13-24
4. Reagan D.R., Doebbeling B.N., Pfaller M.A., et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 114 (1991) 101-106
5. Fernandez C., Gaspar C., Torrellas A., et al. A double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of mupirocin calcium ointment for eliminating nasal carriage of Staphylococcus aureus among hospital personnel. J Antimicrob Chemother 35 (1995) 399-408
6. Boelaert J.R., Van Landuyt H.W., Gordts B.Z., De Baere Y.A., Messer S.A., and Herwaldt L.A. Nasal and cutaneous carriage of Staphylococcus aureus in hemodialysis patients. the effect of nasal mupirocin. Infect Control Hosp Epidemiol 17 (1996) 809-811
7. Perl T.M., Cullen J.J., Wenzel R.P., et al. Intranasal mupirocin to prevent postoperative Staphylococcus aureus infections. N Engl J Med 346 (2002) 1871-1877
8. Shrestha N.K., Shermock K.M., Gordon S.M., et al. Predictive value and cost-effectiveness analysis of a rapid polymerase chain reaction for preoperative detection of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 24 (2003) 327-333
9. Mangram A.J., Horan T.C., Pearson M.L., Silver L.C., and Jarvis W.R. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol 20 (1999) 250-280
10. Eriksen N.H., Espersen F., Rosdahl V.T., and Jensen K. Carriage of Staphylococcus aureus among 104 healthy persons during a 19-month period. Epidemiol Infect 115 (1995) 51-60
11. Nouwen J.L., Ott A., Kluytmans-Vandenbergh M.F., et al. Predicting the Staphylococcus aureus nasal carrier state. derivation and validation of a "culture rule". Clin Infect Dis 39 (2004) 806-811
12. Herwaldt L.A., Cullen J.J., French P., et al. Preoperative risk factors for nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 25 (2004) 481-484
13. Vas S.I., Conly J., Bargman J.M., and Oreopoulos D.G. Resistance to mupirocin. no indication of it to date while using mupirocin ointment for prevention of Staphylococcus aureus exit-site infections in peritoneal dialysis patients. Perit Dial Int 19 (1999) 313-314
14. Annigeri R., Conly J., Vas S., et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 21 (2001) 554-559
15. Lobbedez T., Gardam M., Dedier H., et al. Routine use of mupirocin at the peritoneal catheter exit site and mupirocin resistance. still low after 7 years. Nephrol Dial Transplant 19 (2004) 3140-3143
16. Gales A.C., Andrade S.S., Sader H.S., and Jones R.N. Activity of mupirocin and 14 additional antibiotics against staphylococci isolated from Latin American hospitals. report from the SENTRY antimicrobial surveillance program. J Chemother 16 (2004) 323-328
17. Deshpande L.M., Fix A.M., Pfaller M.A., and Jones R.N. Emerging elevated mupirocin resistance rates among staphylococcal isolates in the SENTRY antimicrobial surveillance program (2000). correlations of results from disk diffusion, Etest and reference dilution methods. Diagn Microbiol Infect Dis 42 (2002) 283-290
18. Perez-Fontan M., Rosales M., Rodriguez-Carmona A., Falcon T.G., and Valdes F. Mupirocin resistance after long-term use for Staphylococcus aureus colonization in patients undergoing chronic peritoneal dialysis. Am J Kidney Dis 39 (2002) 337-341
19. Walker E.S., Vasquez J.E., Dula R., Bullock H., and Sarubbi F.A. Mupirocin-resistant, methicillin-resistant Staphylococcus aureus. does mupirocin remain effective?. Infect Control Hosp Epidemiol 24 (2003) 342-346
20. Miller M.A., Dascal A., Portnoy J., and Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 17 (1996) 811-813
21. Praz S.M., de Torrente A., Zender H., Schmied E., Schleppy C.A., and Genne D. Toxic epidermal necrolysis after topical intranasal application of mupirocin. Infect Control Hosp Epidemiol 24 (2003) 459-460